Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
$PTIX
Biotechnology: Pharmaceutical Preparations
Health Care
Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2021 | $4.00 | Buy | Maxim Group |
SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)
SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)
SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact on PTSD, Depression, Anxiety, Addiction, and ObesityNEW YORK, NY / ACCESSWIRE / May 22, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the complete safety data set from the single dose portion of its Phase 1 trial involving PT00114, its synthesized version of a natural stress-regulating brain peptide. The trial, which included 30 subjects across five cohorts receiving doses up to 1,000 micrograms, reported zero clinically-relevant a
4 - Protagenic Therapeutics, Inc.\new (0001022899) (Issuer)
Maxim Group initiated coverage of Protagenic Therapeutics with a rating of Buy and set a new price target of $4.00
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next monthNEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023."In 2023, Protagenic Therapeutics achieved a significant milestone as we began enrol
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th.Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/PTIX2023. After the regular business of the shareholder is concluded, Executive Chairman Garo Armen, PhD., is expected to provide comments on the progress of the Company's ongoing Phase I clinical tria
4 - Protagenic Therapeutics, Inc.\new (0001022899) (Issuer)
4 - Protagenic Therapeutics, Inc.\new (0001022899) (Issuer)
4 - Protagenic Therapeutics, Inc.\new (0001022899) (Issuer)
8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. Renovaro (NASDAQ:RENB) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. Altamira Therapeutics (NASDAQ:CYTO) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. Purple Biotech (NASDAQ:PPBT) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. P3 Health Partners (NASDAQ:PIII) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 millio
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence